Tried and True Therapies in Advancements for Lung Cancer

Colonel Eli Lilly once said, “Take what you find here and make it better,” which is a founding principle we continue to honor at Lilly to this day. One way we are advancing our mission is to speed innovation. It’s our goal to shorten the amount of time it takes to bring new medicines and therapy regimens to people who are fighting cancer.

Lung cancer, like many others, continues to find ways around the therapies developed so as to grow and spread. Because of this, we have seen a lot of movement to advance care for patients living with this disease. Adding treatments to a cancer regimen is not uncommon, but sometimes unexpected breakthroughs happen when we combine a standard-of-care therapy with other molecules. Studying standard-of-care therapies in combination with newer medicines is one way that we at Lilly are collaborating with others in the industry to speed up innovation. We are proud of our established portfolio of medicines that can serve as the backbone to innovation for newer combination therapies that are novel in their own right and hold the potential to improve cancer care. Recently released data for one such trial in lung cancer has created discussion around its potential to change the way this cancer is treated.

With these recent advances in care, patients living with lung cancer can expect stronger outcomes and to live longer, healthier lives. We are proud to work with our industry partners to ensure health care professionals have access to the right treatment, for the right patient, at the right time.